Double-Blind, Placebo-Controlled, Dose-Escalation Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VIS410) to Influenza Type A Hemagglutinin
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2016
At a glance
- Drugs VIS 410 (Primary)
- Indications Influenza A virus H5N1 subtype; Influenza A virus H7N9 subtype
- Focus Adverse reactions
- Sponsors Visterra
- 26 Feb 2016 Results from this trial were published in the journal EBioMedicine, according to a Visterra Inc. media release.
- 26 Feb 2016 Results published in a Visterra Inc. media release.
- 13 May 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History